Skip to main content

Companion Diagnostic Assay: Introduction and Regulatory Perspective

 A companion diagnostic assay, as defined by the FDA, is a test that provides essential information for the safe and effective use of a corresponding therapeutic product. For gene therapies that use adeno-associated virus (AAV) vectors, an FDA-approved companion diagnostic can help identify patients likely to benefit from therapy by screening for factors such as pre-existing anti-AAV antibodies. Such a companion assay is especially valuable in gene therapy, where pre-existing immunity can significantly influence efficacy and safety.

Key FDA Requirements for Companion Diagnostics

  1. Definition and Regulatory Oversight

    • The FDA defines a companion diagnostic as a test essential for the therapeutic’s safe and effective use. This could mean identifying patients who may benefit from the therapy, avoiding patients likely to experience adverse reactions, or helping to tailor treatment plans.
    • Companion diagnostics typically require FDA premarket approval (PMA) or clearance under a specific pathway (often as an In Vitro Diagnostic or IVD device), particularly if it is integral to the decision-making process for an FDA-approved drug or therapy.

  2. Examples of FDA Expectations for Companion Diagnostics

    • Analytical Validity: Assays must demonstrate that they accurately detect the biomarker of interest (e.g., anti-AAV antibodies) with high sensitivity and specificity. The assay’s performance (precision, repeatability, reproducibility) must be thoroughly validated.
    • Clinical Validity: Evidence must show that the biomarker detected by the assay is relevant to the clinical outcome. In the case of anti-AAV antibody assays, there should be data linking antibody levels to therapeutic efficacy or safety, showing that patients with certain antibody levels are more likely to benefit or have adverse reactions.
    • Clinical Utility: The assay must demonstrate that it positively impacts patient care, for example, by identifying patients with high anti-AAV titers who may require immune modulation before treatment or those ineligible for AAV therapy due to high titers.

  3. Steps for FDA Approval of a Companion Diagnostic Assay

    • Pre-Submission and Planning: Sponsors typically engage in pre-submission meetings with the FDA to clarify the regulatory pathway, discuss study design, and establish testing standards.
    • Assay Validation:
      • Analytical Validation: Demonstrate assay accuracy, precision, and robustness. This often involves validating in a real-world clinical lab setting.
      • Clinical Validation: Conduct studies that show the test’s results can predict outcomes related to AAV therapy, like efficacy or adverse events. Data may come from clinical trials of the AAV therapy that uses the diagnostic as part of its eligibility screening.
    • Clinical Trials: Companion diagnostics for gene therapy are often tested in parallel with the therapy in clinical trials, using trial data to assess the assay’s ability to predict patient response.
    • Regulatory Submission: The PMA application includes detailed evidence of the assay’s analytical and clinical validity, clinical utility, and data from trials, along with documentation supporting manufacturing quality and control standards.

  4. Considerations for AAV Companion Diagnostics Specifically

    • Population Studies: Different populations (pediatric, adult) may have varying prevalence of anti-AAV antibodies, which may necessitate specific population studies to demonstrate that the assay is effective across demographic groups.
    • Standardization and Harmonization: Given that various AAV serotypes are used in therapy, the FDA may expect multiplexed or serotype-specific assays depending on the therapeutic context.
    • Risk-Benefit Evaluation: The FDA evaluates if the diagnostic effectively mitigates risks, such as identifying patients with high antibody levels who may face safety risks or reduced efficacy.

  5. Post-Market Requirements and Labeling

    • The FDA typically requires companion diagnostics to undergo post-market surveillance, ensuring continued accuracy and utility in clinical settings. For AAV therapies, this could involve monitoring assay performance over time and evaluating data from patients re-tested for anti-AAV antibodies prior to redosing.
    • Labeling for the companion diagnostic will include detailed instructions on interpreting results, threshold levels (e.g., antibody titers predictive of treatment efficacy or safety), and guidance on patient selection or immune modulation protocols.

Practical Example

For an anti-AAV antibody companion diagnostic associated with an AAV gene therapy, the FDA would expect:

  • Specificity for the AAV serotype used in the therapy to ensure accurate screening.
  • Validated Cut-Off Thresholds: The assay must have validated threshold levels for anti-AAV antibody titers that predict therapeutic outcomes, established through clinical trial data.
  • Instructions on Clinical Use: Guidelines for interpreting results and determining patient eligibility, such as thresholds for exclusion, immune modulation needs, or alternative treatment plans.

Summary

FDA-approved companion diagnostics for anti-AAV antibodies are pivotal in selecting appropriate candidates for gene therapy, tailoring dosing, and enhancing safety. The FDA requires stringent validation and robust clinical data demonstrating the assay's utility and reliability in real-world clinical settings. Approval entails a thorough review of analytical and clinical performance, along with post-market surveillance, ensuring the companion diagnostic continuously supports optimal patient outcomes in gene therapy.

Popular posts from this blog

Human Genome Editing: FDA Draft Guidance Summary

Consideration for Developing Gene Editing Product  1. Genome Editing Methods: Genome editing can be achieved through nuclease-dependent or nuclease-independent methods. Nuclease-dependent methods involve introducing site-specific breaks in DNA using technologies like zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), modified-homing endonucleases, and CRISPR-associated (Cas) nucleases. These breaks can lead to modification of the DNA sequence at the cleavage site. Nuclease-independent methods can change DNA sequences without cleaving the DNA and include techniques like base editing and synthetic triplex-forming peptide nucleic acids. The choice of GE technology should consider factors such as the mechanism of action, the ability to target specific DNA sequences, and the potential to optimize components for efficiency, specificity, or stability. 2. Type and Degree of Genomic Modification: Different GE approaches rely on DNA repair pathways such a...
Read more

Stem loop RT-PCR for Detection of siRNA in Animal Tissues

Step Loop RT-PCR for Detection of Small Interfering RNA (siRNA) The recent publications described a novel used the novel method for the detection of siRNAs using a TaqMan®-based approach. This approach utilizes similar strategy that has been used for microRNA detection. The approach is illustrated in below.  In brief, the RT step occurs in the presence of a stem-loop RT primer that is complementary to the last 6–10 bases of the 3′ end of the antisense strand of the target siRNA. The stem-loop primer contains an additional universal sequence at the 5′ end that facilitates a TaqMan-based detection strategy in the subsequent qPCR step. As in the case of microRNA, the forward primer for qPCR is sequence-specific for the target siRNA. For sequence compositions that yield a low predicted melting temperature (Tm), the forward primer is designed as a tailed primer to help increase Tm. Stem Loop PCR for SiRNA Detection Step 1: Preparation of liver and plasma samples for the quanti...
Read more

Human Gene Therapy for Neurodegenerative Diseases: FDA Guidance Summary

  Neurodegenerative diseases are a diverse group of disorders characterized by the progressive degeneration of the central or peripheral nervous system, and they can have various causes and clinical characteristics. This guidance document is a resource for sponsors on different aspects of product development, preclinical testing, and clinical trial design. It acknowledges the unique challenges and considerations associated with developing GT products for such complex and varied diseases. Below are the key summaries from the guidance. CONSIDERATIONS FOR CHEMISTRY, MANUFACTURING AND CONTROLS (CMC) The considerations for Chemistry, Manufacturing, and Controls (CMC) when developing gene therapy (GT) products for the treatment of neurodegenerative diseases are crucial for ensuring the safety and efficacy of these advanced therapies. Here, we will elaborate on the specific CMC considerations outlined in your text: Route of Administration and Product Volume: Neurodegenerative diseases oft...
Read more

FDA Guidance on Studying Multiple Versions of Cellular or Gene Therapy Products in Early-Phase Clinical Trials

 The purpose of this guidance is to offer advice to sponsors interested in conducting early-phase clinical trials for a single disease involving multiple variations of a cellular or gene therapy product. Sponsors aim to gather preliminary safety and efficacy data for these product variations within a single clinical trial. It's important to note that even though multiple product versions are studied together, each version is distinct and typically requires a separate investigational new drug application (IND) submission to the FDA. The primary goal of these early-phase clinical studies is to inform decisions about which product version(s) should be advanced for further development in later-phase trials. As such, these studies are not designed to provide the main evidence of effectiveness needed for a marketing application. They are generally not statistically powered to demonstrate a significant difference in efficacy between the different study arms. In this guidance, the FDA prov...
Read more

ICH Q8 (R2) Pharmaceutical development (CHMP/ICH/167068/04)

 ICH Q8 (R2) is a guideline titled "Pharmaceutical Development" (CHMP/ICH/167068/04). This guideline is part of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) and provides recommendations for the pharmaceutical development of medicinal products. It offers a structured approach to the development of pharmaceutical products to ensure their quality, safety, and efficacy. Here's an elaboration of ICH Q8 (R2): 1. Purpose of ICH Q8 (R2): The primary purpose of ICH Q8 (R2) is to provide a systematic and science-based approach to pharmaceutical development. The guideline aims to facilitate the design and development of high-quality pharmaceutical products that meet the needs of patients and regulatory authorities. 2. Scope: ICH Q8 (R2) applies to the development of all types of pharmaceutical products, including small molecules, biotechnological products, and other complex medicinal products. 3. Pharmaceutical Develop...
Read more